84 results about "Bicyclo Compounds" patented technology

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

The present application provides bicyclic compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.

The invention belongs to the field of medicinal chemistry, and relates to a fused bicyclic compound, in particular to a compound shown in a formula (II), a stereoisomer or pharmaceutically acceptable salt of the compound, a preparation method of the compound, a pharmaceutical composition containing the compound and application of the compound in treating diseases.

This invention provides substituted fused bicyclic compounds as kinase inhibitors and their applications, said substituted fused bicyclic compounds having the structure shown in Formula IIc, wherein R0, A1, A2, B1-B3, D1-D3, R7, and R8 are as defined herein. Compounds of Formula IIc are NUAK1 / 2 inhibitors. Therefore, the compounds of this invention can be used for the treatment and prevention of NUAK1 / 2-mediated diseases, disorders, and conditions, such as cancer, and for the preparation of medicaments for the treatment and prevention of NUAK1 / 2-mediated diseases, disorders, and conditions. (IIc)

The present invention relates to new specific 6-6 or 5-6 fused bicyclic compounds comprising pyrimidine or pyridine useful in the prevention and / or treatment of infectious diseases. In particular, the present invention relates to a compound of formula (I) wherein: Ar1 is a (C5-C11)arylene or (C5-C11)heteroarylene group, X is —CH—, —S—, —NR5 or —N—, Y is —CH—, —NR5—S— or —NR6—CH2—, T is —CH— and Q is —CH— or T is —N— and Q is —CR10— or —N—, provided that one or two of X, Q and Y comprise a heteroatom, and with the proviso that, at least one of R1, R2, and, if present, R5 or R6, contains a group —NH-Alk-NR3R4. The inventors showed that compounds of formula (I) present an activity against both W2 and 3D7 Plasmodium falciparum strains, an activity against T. brucei brucei but also an activity against SARS-CoV-2 virus, and that they are positive for G4 recognition. The invention also relates to the preparation process and to the therapeutic uses of the compounds of formula (I).

Provided herein are compounds and compositions thereof for modulating hepatocyte growth factor. In some embodiments, the compounds and compositions are provided for the treatment of diseases, including neurological disorders.

Compounds of formula (I) or pharmaceutically acceptable salts thereof are described, wherein the substituents are as defined herein. Pharmaceutical compositions containing the compounds and methods of using them are also described. [Formula 1] JPEG2022550641000139.jpg4051

The present invention provides fused bicyclic compounds of formula (I), which are therapeutically useful as SMARCA2 and / or SMARCA4 degraders. These compounds are useful in the treatment and / or delaying progression of disease or disorder dependent upon SMARCA2 and / or SMARCA4 in a subject. The present invention also provides pharmaceutical compositions comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof.

Disclosed herein are bicyclic compound derivatives used as inhibitors of cyclin-dependent kinases. Disclosed herein is the use of these inhibitors for inhibiting cyclin-dependent kinases, and the use of such compounds for treating cancer.

The present application relates to the field of pharmaceutical chemistry, and relates to a fused bicyclic compound and a use thereof, and in particular to a fused bicyclic compound, a preparation method for the compound, a pharmaceutical composition containing the compound, and a use of the compound in the treatment of diseases. The structure of the fused bicyclic compound is represented by formula (I).

The invention provides an electrolyte, a battery, a battery pack and electric equipment. The electrolyte comprises a first additive and a second additive, wherein the first additive is a bicyclic compound, each cyclic group of the bicyclic compound comprises a sulfur-containing functional group, and the second additive comprises a silane group. According to the design of the electrolyte, the first additive and the second additive are introduced, and under the synergistic cooperation of the first additive and the second additive, the battery impedance is reduced, and the cycle life of the battery is prolonged.

The present invention belongs to the field of extraction and separation technology of traditional Chinese medicine, and relates to an azabicyclic compound in purslane, an extraction and separation method, and an application thereof. The new compound has a molecular formula of C6H7NO3 and is named 4-ethyl-3-oxa-1-azabicyclo[2.1.1]hexane-2,5-dione according to its structure. A method for extracting and separating the new compound is also provided, which sequentially uses ethanol reflux extraction, ODS column chromatography, dextran gel chromatography, and high-performance liquid chromatography for separation, purification, and preparation. Its structure is determined to be a new compound using mass spectrometry, hydrogen spectrum, carbon spectrum, and two-dimensional nuclear magnetic spectrum analysis methods, and it has anti-inflammatory activity. The new compound of the present invention and its salts or derivatives can be used as raw materials for drug development and pharmacological activity research.

Formula (I) (in the formula, rings A, W, X, Y, L 1 , R 1 , R 3 and R 4 Compounds of Formula (I), and pharmaceutically acceptable salts thereof, are useful for treating or preventing cancer or immune-related diseases or conditions. Also described are pharmaceutical compositions of the compounds of Formula (I), and methods of using such compounds and compositions.

The present invention relates to a crystalline form of Compound 1, a pharmaceutical composition comprising said crystalline form, and the use of said pharmaceutical composition in the treatment of disease. The invention also relates to a preparation method of the compound 1 and the crystal form thereof.

Disclosed is a process for preparing asymmetrically substituted bicyclic compound of formula (III) or (IV) from a compound of formula (I) by pairing a compound of formula (II) with a carbene ligated transition-metal catalyst or a precursor in the presence of a hydride source, wherein the structure of the compound of formula (II) is used as one of the key factors that can alter the selectivity of (III) and (IV) under a given condition.

Bicyclic nitrogen-containing compounds of Formula (I), pharmaceutical compositions comprising these compounds, and their use in the treatment of bacterial infections are described. (see Formula).

The invention discloses an electrolyte of a lithium iron phosphate ion battery, a preparation method of the electrolyte and the lithium iron phosphate ion battery. The lithium iron phosphate ion battery comprises an organic solvent system, a lithium salt system and an additive system, the organic solvent system comprises at least one cyclic carbonate and at least one chain carbonate; the additive system comprises a chalcogenide bicyclic compound, and the chalcogenide bicyclic compound has the following structural formula; x and Y are respectively and independently selected from any one of P, B and P = O; a and B are respectively and independently selected from any one of O, a carbonyl group, a sulfinyl group, a sulfuryl group, a substituted or unsubstituted C1-C6 alkylene group, a substituted or unsubstituted C2-C10 alkenyl group, a substituted or unsubstituted C2-C10 alkynyl group, a substituted or unsubstituted C2-C10 cyano group and an aryl group; according to the invention, a reliable and stable low-impedance interface can be formed, and the cycle performance and the service life of the lithium iron phosphate ion battery are obviously enhanced.

Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N‑oxides, and salts thereof, 1 wherein R1, R3, L, A and m are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling and combating an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the disclosure.

Disclosed are compounds having Formula 1, including all geometric and stereoisomers, N-oxides and salts thereof, where L, R1, m, R2, R3 and R4 are as defined in the disclosure. Also disclosed are compositions containing these compounds of Formula 1, and methods for controlling and combating an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or composition of the disclosure.

Disclosed herein are bicyclic compounds, including pharmaceutical compositions containing one or more such compounds. Methods of making functionalized bicyclic compounds are also disclosed. Also disclosed herein are methods of treating diseases and / or conditions (e.g., inflammation and / or cancer) with the bicyclic compounds disclosed herein.

A compound represented by formula (I), isomers or pharmaceutically acceptable salts thereof, and application thereof in the preparation of drugs for treating diseases related to RIP-1 (receptor interacting protein) kinase.

Disclosed is a compound of Formula (I), or a stereoisomer, tautomer, or salt or solvate thereof, wherein all variables are as defined herein. The compounds modulate the activity of farnesoid X receptor (FXR), e.g., as agonists. Also disclosed are pharmaceutical compositions comprising the compounds, and methods of treating diseases, disorders, or conditions associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

The disclosure relates to fused bicyclic compounds comprising ring cores such as 2H-benzo[e][1,3]oxazin-4(3H)-one, 2,3-dihydrothieno[2,3-e][1,3]oxazin-4-one and 2,3-dihydrothieno[3,2-e][1,3]oxazin-4-one, that act as allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds, optionally in combination with a second active agent; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.

Disclosed herein are bicyclic compound derivatives useful as cyclin dependent kinase inhibitors. Disclosed herein are the use of these inhibitors for inhibiting cyclin-dependent kinases, and the use of these compounds for the treatment of cancer.

The present invention relates to a bicyclic-type MAT2A inhibitor and use thereof. Specifically, the present invention discloses a bicyclic compound represented by formula (I) or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a racemate, an atropisomer, a polymorph, a solvate, or an isotope labeled compound thereof. The compound represented by formula (I) has MAT2A enzyme inhibitory activity, can be used as a good MAT2A inhibitor, and is further used for preparing drugs for treating and / or preventing MTAP-related diseases, especially tumors.

The disclosure provides novel substituted fused heteroaromatic compounds as represented in Formula I, wherein A1-A6 and R1-R4 are defined herein. The compounds of Formula I are kinase inhibitors, especially ATR kinase inhibitors. Therefore, the compounds of the disclosure may be used to treat ATR-mediated diseases, disorders and conditions, such as cancer.

The present invention relates to condensed piperidinyl bicyclic, metasubstituted piperidinyl, and related compounds thereof that modulate the activity of the mammalian C5a receptor by directly binding to it, for use in treating diseases, particularly monosodium urate (MSU) induced diseases, neutrophil-induced inflammatory kidney diseases, cutaneous neutrophil inflammatory diseases, and immune complex diseases.

The present invention relates to compounds that have activity as cluster of differentiation 38 (CD38) inhibitors, compositions of such compounds, and methods using such compounds for preventing or treating diseases and disorders such as, for example, diseases and disorders of metabolism.